Literature DB >> 9287314

Human fibroblasts prefer mannose over glucose as a source of mannose for N-glycosylation. Evidence for the functional importance of transported mannose.

K Panneerselvam1, J R Etchison, H H Freeze.   

Abstract

Mannose in N-linked oligosaccharides is assumed to be derived primarily from glucose through phosphomannose isomerase (PMI). The discovery of mammalian mannose-specific transporters that function at physiological concentrations suggested that mannose might directly contribute to oligosaccharide synthesis. To determine the relative contribution of glucose and mannose, human fibroblasts were labeled with either [2-3H]mannose or [1,5,6-3H]glucose at the same specific activity, and the N-linked chains were released by PNGase F digestion. Most of the trichloroacetic acid-precipitable [3H]mannose label was released by this digestion, but only about 10% of the trichloroacetic acid-precipitable material was released from cells labeled with [1,5,6-3H]glucose. Both sugars labeled a similar array of oligosaccharides, and acid hydrolysis of these chains showed that [2-3H]mannose contributed 65-75% of the [3H]mannose in cells labeled for 1 h, despite the 100-fold higher concentration of exogenous glucose. Mannose consumption and [2-3H]mannose utilization were within the range of rates expected for mannose transport via the mannose-specific transporter. About 7-14% of the [2-3H]mannose is used for glycosylation, while the rest (86-93%) is catabolized to 3H2O via PMI. Increasing the exogenous mannose concentration beyond mannose transporter saturation results in the conversion of >99% of [2-3H]mannose into 3H2O. Long term labeling of cells with [2-3H]mannose showed that the specific activity of mannose in glycoproteins reached 77% of the specific activity of [2-3H]mannose added to the medium. These results show that when fibroblasts are provided with physiological concentrations of mannose, they use the mannose-specific transporter to supply the majority of mannose needed for glycoprotein synthesis. PMI may normally be used to catabolize excess mannose rather than to primarily supply Man-6-P for glycoprotein synthesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287314     DOI: 10.1074/jbc.272.37.23123

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Transplacental supply of mannose and inositol in uncomplicated pregnancies using stable isotopes.

Authors:  Barton C Staat; Henry L Galan; Jeri E F Harwood; Gene Lee; Anna Maria Marconi; Cinzia L Paolini; Alex Cheung; Frederick C Battaglia
Journal:  J Clin Endocrinol Metab       Date:  2012-04-27       Impact factor: 5.958

2.  The metabolic origins of mannose in glycoproteins.

Authors:  Mie Ichikawa; David A Scott; Marie-Estelle Losfeld; Hudson H Freeze
Journal:  J Biol Chem       Date:  2014-01-09       Impact factor: 5.157

Review 3.  KDN (deaminated neuraminic acid): dreamful past and exciting future of the newest member of the sialic acid family.

Authors:  Sadako Inoue; Ken Kitajima
Journal:  Glycoconj J       Date:  2006-07       Impact factor: 2.916

Review 4.  Metabolic manipulation of glycosylation disorders in humans and animal models.

Authors:  Hudson H Freeze; Vandana Sharma
Journal:  Semin Cell Dev Biol       Date:  2010-04-02       Impact factor: 7.727

5.  Regulation of the dolichol pathway in human fibroblasts by the endoplasmic reticulum unfolded protein response.

Authors:  W T Doerrler; M A Lehrman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

6.  Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.

Authors:  R Niehues; M Hasilik; G Alton; C Körner; M Schiebe-Sukumar; H G Koch; K P Zimmer; R Wu; E Harms; K Reiter; K von Figura; H H Freeze; H K Harms; T Marquardt
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

7.  Clinical significance of plasma mannose concentrations in healthy and diabetic dogs.

Authors:  A Mori; T Sato; P Lee; M Furuuchi; H Tazaki; K Katayama; H Mizutani; T Sako; T Arai
Journal:  Vet Res Commun       Date:  2008-12-13       Impact factor: 2.459

Review 8.  Glycosylation diseases: quo vadis?

Authors:  Harry Schachter; Hudson H Freeze
Journal:  Biochim Biophys Acta       Date:  2008-11-13

9.  Ultrasonic disintegration of microalgal biomass and consequent improvement of bioaccessibility/bioavailability in microbial fermentation.

Authors:  Byong-Hun Jeon; Jeong-A Choi; Hyun-Chul Kim; Jae-Hoon Hwang; Reda Ai Abou-Shanab; Brian A Dempsey; John M Regan; Jung Rae Kim
Journal:  Biotechnol Biofuels       Date:  2013-03-18       Impact factor: 6.040

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.